$HAE

Investing.com's AI strategy exited Haemonetics (HAE) at $103.07, up 89% from its $54.54 entry a year prior. The gain followed a commercial deal with CSL Plasma, a fiscal Q1 beat, and analyst price target increases. Nucor (NUE) also rose 4.2% this week after raising prices and reporting strong earnings.

Analysts updated price targets for several companies. Baird raised Ross Stores (ROST) target to $270, Parsons (PSN) to $57, and Deere (DE) to $640. BTIG cut Walmart (WMT) target to $140. HSBC raised Ternium (TX) target to $55. Rothschild & Co increased Equifax (EFX) target to $235. Other changes include Envoy Medical (COCH), MDxHealth (MDXH), Hometrust Bancshares (HTB), and Haemonetics (HAE).

Haemonetics (HAE) announced a new deal with CSL Plasma to supply its NexSys PCS platforms and apheresis kits for U.S. plasma collection centers. The contract, following FDA approval, does not have minimum purchase requirements. HAE shares rose 15% in after-hours trading, reaching $107. Analysts estimate potential revenue of $183M-$223M annually if CSL fully switches back, with a 6%-8% growth rate and 10%-20% pricing premium.

Haemonetics Corp (HAE) hit a 52-week high of $106.64, up 92.73% over a year. The medical tech firm's stock has surged 72.49% in six months and 14.57% in the past week. Q1 earnings beat estimates, with revenue at $339M. BTIG raised its price target to $96. HAE signed a supply deal with CSL Plasma.

Haemonetics Corporation (NYSE:HAE) rose 15.9% after announcing a supply agreement with CSL Plasma, adding to its 91.88% surge since being identified by InvestingPro's AI models. The company reported Q1 2027 revenue of $339.4M and adjusted EPS of $1.14, raising its full-year revenue growth outlook to 5-8%. InvestingPro's AI-powered stock picker has identified multiple stocks with significant gains, including Haemonetics, which was highlighted for its valuation, profitability, and growth potential

Haemonetics (HAE) shares rose about 6.6% in pre-open after the company filed an 8-K for a non-exclusive supply agreement with CSL Plasma. The deal lets CSL deploy Haemonetics NexSys PCS devices with Persona PLUS and buy related disposables at U.S. centers. Investors also cited Haemonetics’ Aug. 6 Q1 FY2027 results: $339.4M revenue, $1.14 adjusted EPS, and raised FY2027 growth guidance to 5%–8%, plus analyst target increases.

Haemonetics (HAE) reported fiscal Q1 2027 adjusted EPS of $1.14, up 3.6% and 6.5% above the Zacks consensus. Revenue rose 5.6% to $339.4 million, beating consensus. Management raised fiscal 2027 revenue guidance to 5-8% growth and organic growth to 4-7%.

Haemonetics (HAE) reported Q1 FY2027 net revenue of $339.4 million, up 5.6% reported and 5.9% organic. Adjusted EPS was $1.14. Management raised FY2027 revenue guidance to 5% to 8% reported and 4% to 7% organic, citing momentum in Plasma and MedSurg, plus higher cash flow and debt paydown.

Investing.com reports Berkshire Hathaway turned net buyer in Q2 2026, buying $23.5B of equities versus $3.7B sold, for about $19.8B net purchases, including a $10B stake in Alphabet. The article lists stocks it says rose sharply, including MATV, CCB, DIOD, IT, and HIMX, citing August and earnings figures for CCB and HIMX.

Haemonetics reported Q2 momentum driven by Plasma share gains and early Persona PLUS rollout, with adopters citing plasma yield improvements above 5%. Interventional Technologies growth rebounded on VASCADE MVP XL expansion and real-world evidence, while Hemostasis Management disposables grew mid-teens. Management expects margin resilience from mix, pricing, and cost discipline, and monitors Persona PLUS adoption and VASCADE MVP XL launches. Shares trade around $84.98.